The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Kidney Neoplasms , 38 publications
- Carcinoma, Renal Cell , 28 publications
- Nephrectomy , 20 publications
- Prostatic Neoplasms , 17 publications
Research activity
Active clinical trials
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as…
- Investigator
- Paul L Crispen
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
93 publications
2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
European urology focus
PubMed • Publisher's site2023
Editorial Comment.
The Journal of urology
PubMed • Publisher's site2023
Hyaluronan Metabolism in Urologic Cancers.
Advanced biology
PubMed • Publisher's site2023
Micro-Ultrasound Guided Transperineal Prostate Biopsy: A Clinic-Based Procedure.
Journal of visualized experiments : JoVE
PubMed • Publisher's site2023
Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
Methods in molecular biology (Clifton, N.J.)
PubMed • Publisher's site